NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $152.3 million in its first quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $2.19.

The results missed Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was for a loss of $1.76 per share.

The biotechnology company posted revenue of $79.9 million in the period, also missing Street forecasts. Eight analysts surveyed by Zacks expected $84.3 million.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News